PRIME MEMBER EXCLUSIVE | 3 Months Free Trial

Auto-renews at INR 199/mo after 3 months. Cancel anytime. Offer ends 15 July, 2026.
Medtronic Q4 2026 Earnings Analysis cover art

Medtronic Q4 2026 Earnings Analysis

Medtronic Q4 2026 Earnings Analysis

Listen for free

View show details
More earnings analysis: https://betafinch.com
Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
──────────
# Beta Finch Podcast Script: Medtronic Q4 2026 Earnings

**ALEX:** Welcome back to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that matter. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're unpacking Medtronic's fourth quarter 2026 results, and folks, this is a company that's clearly hitting its stride.

Before we dive in, I need to share an important disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex, and wow - where do we even start with Medtronic? These numbers are impressive. The company just posted $9.8 billion in Q4 revenue, up nearly 10% reported and 6.6% organically. But here's what really caught my attention - this caps off their strongest annual performance in a decade.

**ALEX:** That's right, Jordan. For the full fiscal year, they hit $36.4 billion in revenue with 8.4% reported growth and 5.8% organic growth. CEO Geoff Martha was clearly proud of these results, calling it a reflection of their "commitment to operational rigor" while investing in durable growth. But let's talk about what's really driving this performance.

**JORDAN:** The star of the show has got to be their Cardiac Ablation Solutions business - or CAS. This division delivered 78% worldwide growth and gained 8 points of U.S. market share. Their PFA technology saw 145% global growth, with their Sphere-9 catheter continuing to show "broad versatility," as Martha put it.

**ALEX:** And here's what's really exciting about CAS - they're still in the "early innings," as CFO Thierry Pieton noted. The company increased their installed base by 40% just in the fourth quarter alone. They're now annualizing over $2 billion in revenue and are on track to hit that $2 billion trailing mark in the first quarter of fiscal 2027. That's massive scale in a high-growth market.

**JORDAN:** What I found fascinating was Martha's comment about "completely surrounding the electrophysiology space." They're not just selling one product - they're building an entire ecosystem. They launched Sphere-9 in Japan, got FDA approval for a U.S. VT pivotal trial, and even announced two targeted investments in ICE catheter technology this morning.

**ALEX:** Speaking of investments, let's talk about their capital allocation strategy because this is where you really see the company's long-term vision. In Q4 alone, they closed or announced nearly $2 billion in additional investments through M&A and venture deals. They acquired CathWorks for their AI-powered FFRangio system, announced plans to buy Scientia for neurovascular guidewire tech, and made investments in everything from chronic pain management to pulmonary artery denervation.

**JORDAN:** That's a great point, Alex. And it's not just about buying technology - it's about strategic positioning. Take their Symplicity Spyral system for treating hypertension. This business is now annualizing at $100 million, and they've doubled their weekly procedure volumes since getting the NCD coverage decision. Martha emphasized that 18 million Americans still have uncontrolled hypertension despite multiple medications - that's a massive addressable market.

**ALEX:** Let's shift to the numbers that investors will be watching closely. For fiscal 2027, Medtronic is guiding to organic revenue growth of 6.75% to 7.25%. Now, there's an extra selling week baked into that, which adds about 125 basis points, but even adjusting for that, we're looking at solid mid-single-digit growth acceleration.

**JORDAN:** The guidance is particularly interesting because of how they're handling the MiniMed diabetes business. They completed the IPO in March, but

This episode includes AI-generated content.
adbl_web_anon_alc_button_suppression_t1
No reviews yet